Novo Nordisk UK stockpiling medicines in case of 'no deal'

As the biggest supplier of insulin in the UK, the consequences of Danish diabetes company Novo Nordisk (NOV: N) failing to get its products through customs could be disastrous if there are hold-ups due to a ‘no deal’ Brexit.

Thankfully, the company is increasing stock of insulin products to approximately 16 weeks from the fourth quarter of 2018 as part of its preparations for the ‘no deal’ scenario of the UK and European Union (EU) going their separate ways without an agreement.

Pinder Sahota, corporate vice president of Novo Nordisk UK, said: “Our first commitment is to ensure that patients treated with our medicines remain unaffected in the event of a ‘no-deal’ Brexit. We are working closely with trade associations in the UK and the EU to ensure that the interests of our patients are at the forefront of negotiations.